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Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of autosomal dominant familial Parkinson’s
disease (PD). LRRK2 encodes a multi-domain protein containing GTPase and kinase enzymatic domains. Disease-associated
mutations in LRRK2 variably influence enzymatic activity with the common G2019S variant leading to enhanced kinase
activity. Mutant LRRK2 induces neuronal toxicity through a kinase-dependent mechanism suggesting that kinase activity is
important for mediating the pathogenic effects of LRRK2 mutations. A number of LRRK2 kinase substrates have been
identified in vitro but whether they represent authentic physiological substrates in mammalian cells or tissues is not yet
clear. The eukaryotic initiation factor 4E (eIF4E)-binding protein, 4E-BP1, was recently identified as a potential substrate of
LRRK2 kinase activity in vitro and in Drosophila with phosphorylation occurring at Thr37 and Thr46. Here, we explore a
potential interaction of LRRK2 and 4E-BP1 in mammalian cells and brain. We find that LRRK2 can weakly phosphorylate 4E-
BP1 in vitro but LRRK2 overexpression is not able to alter endogenous 4E-BP1 phosphorylation in mammalian cells. In
mammalian neurons LRRK2 and 4E-BP1 display minimal co-localization, whereas the subcellular distribution, protein
complex formation and covalent post-translational modification of endogenous 4E-BP1 are not altered in the brains of
LRRK2 knockout or mutant LRRK2 transgenic mice. In the brain, the phosphorylation of 4E-BP1 at Thr37 and Thr46 does not
change in LRRK2 knockout or mutant LRRK2 transgenic mice, nor is 4E-BP1 phosphorylation altered in idiopathic or G2019S
mutant PD brains. Collectively, our results suggest that 4E-BP1 is neither a major nor robust physiological substrate of LRRK2
in mammalian cells or brain.
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Introduction
Mutations in the leucine-rich repeat kinase 2 (LRRK2, PARK8) gene
cause late-onset, autosomal dominant Parkinson’s disease (PD),
and represent the most common cause of inherited PD [1,2,3].
LRRK2 mutations are also prevalent in sporadic PD in some
populations, whereas more common genetic variation in the
LRRK2 gene associates with PD in genome-wide association
studies [1,3,4,5]. The clinical, neurochemical and neuropatholog-
ical spectrum of LRRK2-linked PD is largely indistinguishable from
idiopathic PD [1,6,7,8]. Therefore, LRRK2 plays an important role
in the development of familial and sporadic PD.
The LRRK2 gene encodes a large multi-domain protein
belonging to the ROCO protein family [9]. LRRK2 contains a
Ras-of-Complex (ROC) GTPase domain and a C-terminal of
ROC (COR) domain followed by a serine/threonine kinase
domain with similarity to the mixed-lineage kinase family.
Surrounding the central ROC-COR-kinase catalytic core region
are a number of putative protein-protein interaction domains
including N-terminal ankyrin and armadillo-like repeats, a
leucine-rich repeat region, and a C-terminal WD40-like repeat
domain. Mutations known to cause PD are clustered within the
central catalytic region including the GTPase (N1437H, R1441C,
R1441G and R1441H), COR (Y1699C) and kinase (G2019S and
I2020T) domains [9]. Mutations alter enzymatic activities that
include enhanced kinase activity (i.e. G2019S and N1437H)
[10,11,12], reduced GTPase activity (i.e. R1441C/G/H and
Y1699C) [13,14,15,16] or enhanced GTP-binding (i.e. N1437H,
R1441C/G/H and Y1699C) [17] of LRRK2. LRRK2 mutations
have also been shown to enhance neuronal toxicity compared to
the wild-type (WT) protein through a mechanism dependent on
kinase and/or GTPase activity [17,18,19,20]. Therefore, alter-
ations in the enzymatic activity of LRRK2 due to pathogenic
mutations are most likely important for the development of PD.
LRRK2 can act as a functional kinase in vitro whereby it can
mediate autophosphorylation or phosphorylation of generic kinase
substrates (i.e. myelin basic protein) [10,17,18,21,22,23,24]. The
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most common mutation, G2019S, is located within a DYG motif
within the kinase activation domain and robustly enhances kinase
activity [11]. A number of putative substrates for LRRK2 kinase
activity have been identified in vitro including moesin [22], 4E-BP1
[25], b-tubulin [26], FoxO1 [27], MAPKK proteins [28,29] and
ArfGAP1 [30,31], but it is unclear whether these proteins act as
physiological substrates of LRRK2 in mammalian cells or tissues.
4E-BP1 is known to function as a repressor of protein translation
by binding to the eukaryotic translation initiation factor, eIF4E,
leading to inhibition of cap-dependent translation [32]. Phosphor-
ylation of 4E-BP1 at Thr37 and Thr46 serves to prime subsequent
phosphorylation at Ser65 and Thr70 which disrupts the interac-
tion with eIF4E and results in the activation of protein translation
[33,34].
4E-BP1 was previously suggested to be a LRRK2 substrate with
phosphorylation occurring at two specific residues, Thr37 and
Thr46 [25]. Both human LRRK2 and Drosophila LRRK (dLRRK)
mediated the phosphorylation of human 4E-BP1 or d4E-BP,
respectively, in vitro. Silencing of dLRRK reduced whereas
dLRRK overexpression enhanced d4E-BP phosphorylation at
Thr37/46 in Drosophila [25,35]. Furthermore, the overexpression
of human LRRK2 enhanced the phosphorylation of 4E-BP1 at
Thr37/46 and to a lesser extent at Thr70 in HEK-293T cells [25].
While these observations potentially suggest that 4E-BP1 is a
physiological LRRK2 substrate, a recent study by Kumar and
colleagues suggests that 4E-BP1 may be a relatively weak substrate
of LRRK2 kinase activity in vitro compared to LRRK2 autophos-
phorylation, and they were unable to confirm the phosphorylation
of 4E-BP1 by LRRK2 in cells [36].
To better define a potentially important interaction between
LRRK2 and 4E-BP1, we have explored the effects of LRRK2
expression and pathogenic mutations on the phosphorylation
status of 4E-BP1 in the mammalian brain using transgenic and
knockout mice that are now available. Our data demonstrate that
modulation of LRRK2 expression does not influence 4E-BP1
phosphorylation at Thr37 and Thr46 in mammalian cells or brain
tissue. We conclude that 4E-BP1 is not a major or robust
physiological substrate of LRRK2 in mammalian cells or brain.
Results
Phosphorylation of 4E-BP1 by LRRK2 in vitro but not in
HEK-293T cells
We first sought to confirm the phosphorylation of 4E-BP1 by
LRRK2 in vitro under optimized LRRK2 activity conditions. We
employed recombinant GST-tagged human LRRK2 consisting of
amino acids 970-2527 together with GST-tagged human 4E-BP1
for in vitro kinase assays with [32P]-c-ATP. Notably, the 4E-BP1
recombinant protein was highly soluble and derived from bacteria
and therefore has no inherent phosphorylation modifications. We
could confirm that wild-type (WT) LRRK2 modestly phosphor-
ylates 4E-BP1 whereas kinase-inactive LRRK2 (D1994A) displays
no activity (Fig. 1A). Notably, LRRK2 autophosphorylation is
substantially more efficient than 4E-BP1 phosphorylation in this
assay (Fig. 1A), consistent with recent reports [36]. It is possible
that co-factors are required that are not present in the in vitro
reactions, so we explored LRRK2 phosphorylation of 4E-BP1 in
HEK-293T cells where 4E-BP1 is actively phosphorylated. The
expression of WT or G2019S LRRK2 fails to increase 4E-BP1
phosphorylation at Thr37/46 or Ser65 relative to expression of
D1994A LRRK2 or cells lacking myc-tagged LRRK2 (Fig. 1B).
Collectively, these data confirm that 4E-BP1 is a rather modest
substrate of LRRK2 in vitro and cannot influence additional
phosphorylation on 4E-BP1 in HEK-293T cells even with
overexpression of the kinase-hyperactive G2019S LRRK2.
LRRK2 does not change 4E-BP1 subcellular localization or
protein complexes
Although the phosphorylation of 4E-BP1 by LRRK2 in HEK-
293T cells could not be demonstrated here and also in a previous
study [36], dLRRK has been reported to phosphorylate d4E-BP at
Figure 1. Phosphorylation of 4E-BP1 by LRRK2 in vitro and in mammalian cells. (A) In vitro kinase assay with [32P]-c-ATP, recombinant GST-
tagged human LRRK2 (DN, residues 970–2527) and GST-tagged human 4E-BP1. Coomassie-stained SDS-PAGE gels indicate equal loading of 4E-BP1
and LRRK2 proteins in each condition. Autoradiographs indicate the phosphorylation of 4E-BP1 by WT LRRK2 compared to kinase-inactive D1994A
LRRK2. Autophosphorylation of WT LRRK2 is also detected. (B) Western blot analysis of endogenous 4E-BP1 phosphorylation at Thr37/Thr46 or Ser65
in HEK-293T cells transiently expressing myc-tagged human LRRK2 variants (WT, G2019S and D1994A). LRRK2 overexpression fails to alter 4E-BP1
phosphorylation. Blots are representative of duplicate experiments. Molecular mass markers are indicated in kilodaltons (kDa).
doi:10.1371/journal.pone.0047784.g001
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Thr37/46 in vivo in brain extracts from Drosophila [25]. It is possible
therefore that 4E-BP1 phosphorylation by LRRK2 occurs in a
cell- or tissue-specific manner (e.g. brain tissue). To explore the
relationship between LRRK2 and 4E-BP1 in the mammalian
brain, we assessed the subcellular co-localization of 4E-BP1 and
LRRK2 in rat primary cortical neurons. Cortical cultures were
infected at DIV 6 with recombinant human adenovirus expressing
full-length FLAG-tagged human LRRK2 variants (WT, R1441C
or G2019S), fixed at DIV 16 and subjected to immunocytochem-
istry. Confocal microscopic analysis reveals limited co-localization
of exogenous LRRK2 and endogenous 4E-BP1 occurring in the
cytoplasm of cortical neurons whereas substantial 4E-BP1 also
resides in the nucleus where LRRK2 is largely excluded (Fig. 2A).
LRRK2 pathogenic mutations, R1441C and G2019S, do not
influence 4E-BP1 subcellular localization or the degree of co-
localization with LRRK2 in cortical neurons compared to WT
LRRK2 (Fig. 2A). To isolate a possible interaction in the cytosol,
we conducted subcellular fractionation of cerebral cortex tissue
derived from adult LRRK2 knockout (KO) mice and their WT
control littermates, or human G2019S LRRK2 transgenic and
non-transgenic mice. 4E-BP1 is enriched in the soluble S1, S2 and
S3 fractions and at lower levels in the synaptosomal cytosolic LS1
and synaptic vesicle cytosolic LS2 fractions but is largely excluded
from the nuclear P1 fraction (Fig. 2B). In contrast, LRRK2 is
enriched in the microsomal P3 fraction and at lower levels in the
synaptic vesicle membrane (LP2) and soluble S1 and S2 fractions
(Fig. 2B). Therefore, 4E-BP1 and LRRK2 partly co-localize in the
soluble S1 and S2 fractions but otherwise exhibit distinct
subcellular distribution profiles in adult mouse brain. The
subcellular fractionation profile of 4E-BP1 in brain is not altered
in LRRK2 KO mice or human G2019S LRRK2 transgenic mice
compared to littermate control mice (Fig. 2B). To explore the
impact of LRRK2 expression on 4E-BP1 protein complex
formation, we conducted size-exclusion chromatography on
soluble brain extracts derived from adult WT and LRRK2 KO
mice. The elution profile of total and phosphorylated 4E-BP1 is
similar in WT and KO mouse brain fractions without obvious
differences in the levels of total or phosphorylated (Thr37/46) 4E-
BP1 (Fig. 2C). Collectively, these data reveal that 4E-BP1 and
LRRK2 only partly co-localize in cultured neurons and in soluble
fractions of mouse brain, however, LRRK2 expression does not
influence the subcellular localization, phosphorylation or protein
complex formation of 4E-BP1 in the mouse brain.
LRRK2 does not regulate the phosphorylation of 4E-BP1
at Thr37/46 in mouse brain
To explore the impact of LRRK2 expression and pathogenic
mutations on 4E-BP1 phosphorylation in mouse brain, total 4E-
BP1 was immunoprecipitated from cerebral cortex extracts of WT
and LRRK2 KO mice, or from human R1441C or G2019S
LRRK2 transgenic mice and non-transgenic littermate control
mice. 4E-BP1 immunoprecipitates were analyzed by Western
blotting with antibodies recognizing total or phosphorylated
(Thr37/46) 4E-BP1. The phosphorylation of 4E-BP1 at Thr37/
46 is not altered by LRRK2 deletion or overexpression of mutant
LRRK2 in the cerebral cortex, nor are differences in phospho-
shifts noted using total 4E-BP1 antibodies (Fig. 3A). Similar
observations were made in striatal extracts derived from LRRK2
KO and human LRRK2 transgenic mice compared to control
mice (Fig. 3B). LRRK2 deletion in KO mice is confirmed using an
antibody specific for total LRRK2 (MJFF2) whereas human
LRRK2 expression in transgenic mice is confirmed using a
human-selective LRRK2 antibody (MJFF4) (Fig. 3). Collectively,
these data demonstrate that LRRK2 expression or pathogenic
mutations (G2019S or R1441C) do not influence 4E-BP1
phosphorylation at Thr37/46 in the mouse brain.
LRRK2 does not alter post-translational modifications of
4E-BP1 in cells or brain
As LRRK2 fails to alter 4E-BP1 phosphorylation in mouse
brain tissue, we elected to explore whether LRRK2 expression or
activity could influence the post-translational modification of 4E-
BP1. Such modifications could potentially reveal alternative sites
of 4E-BP1 phosphorylation in addition to other covalent
modifications. To assess the effects of LRRK2 kinase activity on
4E-BP1, extracts from human SH-SY5Y neural cells expressing
FLAG-tagged human LRRK2 variants (WT, G2019S or D1994A)
were resolved by 2D SDS-PAGE and subjected to Western blot
analysis for total 4E-BP1. Endogenous 4E-BP1 is detected as ,6
discrete acidic species of similar molecular mass in SH-SY5Y cells
(Fig. 4A). However, the 2D migration pattern of 4E-BP1 is not
altered by WT or G2019S LRRK2 expression compared to
D1994A LRRK2 expression (Fig. 4A). We next conducted similar
studies on cerebral cortex and striatal extracts derived from
LRRK2 KO and WT mice. 4E-BP1 is detected as 4–5 discrete
acidic species in brain tissue but this 2D migration pattern is not
altered by deletion of LRRK2 (Fig. 4B and C). Collectively, these
data suggest that modulating LRRK2 expression or activity in
human cells or mouse brain does not alter the post-translational
modification of 4E-BP1 consistent with no effect of LRRK2 on
4E-BP1 phosphorylation in vivo.
Phosphorylation of 4E-BP1 at Thr37/46 in idiopathic and
G2019S mutant PD brains
Since we were not able to detect LRRK2-dependent alterations
in 4E-BP1 phosphorylation in human cell lines and mouse brain,
we next sought to determine whether 4E-BP1 phosphorylation is
altered in human brain tissue derived from PD subjects with or
without LRRK2 mutations. Soluble extracts derived from frontal
cortex and basal ganglia of idiopathic or G2019S mutant PD
brains and normal control brains were subjected to Western blot
analysis with antibodies to total or phosphorylated (Thr37/46) 4E-
BP1. In frontal cortex, we observe a significant overall reduction of
total 4E-BP1 levels in G2019S mutant PD brains (in 3 out of 5
subjects) compared to control brains, whereas the level of 4E-BP1
phosphorylation is not different across brain samples (Fig. 5A). In
the basal ganglia, we observe a significant increase of total 4E-BP1
levels in idiopathic (in 5 out of 5 subjects) and G2019S mutant (in
3 out of 4 subjects) PD brains compared to control brains (Fig. 5B).
The levels of phosphorylated 4E-BP1 are significantly reduced in
basal ganglia extracts from idiopathic PD brains compared to
control brains (Fig. 5B). The detection of full-length LRRK2 in
post mortem human brain extracts is problematic and has not
been possible using currently available LRRK2 antibodies. The
apparent alterations in total 4E-BP1 levels in G2019S and iPD
brains, which for G2019S subjects is opposite between frontal
cortex and basal ganglia, could potentially reflect the effects of
various factors, including post mortem delay, agonal state, age,
disease pathology or tissue sampling, since not all subjects reveal a
consistent trend within each group as noted above. Importantly,
we do not observe increased 4E-BP1 phosphorylation in the frontal
cortex or basal ganglia of idiopathic or G2019S mutant PD brains
compared to control brains suggesting that 4E-BP1 phosphoryla-
tion is not altered by LRRK2 pathogenic mutations in the human
brain.
4E-BP1 Phosphorylation Is Not Altered by LRRK2
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Discussion
The identification of physiological substrates for LRRK2 kinase
activity is of major importance for understanding the pathogenic
effects of disease-causing mutations, for understanding the
molecular signaling pathways downstream of LRRK2 activity
but upstream of LRRK2-dependent neuronal toxicity, and as
potential surrogate markers of LRRK2 kinase activity in vivo for
monitoring the actions of kinase inhibitors. To date, only a small
number of putative LRRK2 substrates have been identified in vitro
but none of these proteins have yet been confirmed as
physiological or pathological substrates in mammalian cells or
tissues [9]. Of the putative LRRK2 substrates identified so far, 4E-
BP1 provides one of the more compelling cases since previous
studies have shown that modulating LRRK2 expression in
Drosophila or mammalian cells leads to alterations in 4E-BP1
phosphorylation [25,35]. Despite these observations, a recent
Figure 2. Effect of LRRK2 on 4E-BP1 subcellular localization and protein complex formation. (A) Confocal fluorescence microscopy
reveals minimal co-localization of FLAG-tagged human LRRK2 variants and endogenous 4E-BP1 in rat primary cortical neurons. Pathogenic mutations
(R1441C or G2019S) do not alter the localization of LRRK2 with 4E-BP1 compared to WT LRRK2. Cytofluorograms and co-localization coefficients
(Rcoloc; mean6SEM, n= 5–10 neurons) reveal the extent of co-localization between LRRK2 and 4E-BP1 fluorescent signals. Confocal images are taken
from single z-plane at 0.1 mm thickness. Images are representative of at least five neurons taken from duplicate experiments. Scale bar: 10 mm. (B)
Subcellular fractionation of cerebral cortex from WT and LRRK2 KO mice, or human G2019S LRRK2 transgenic (TG) and non-transgenic (NTG) mice. 4E-
BP1 is enriched in soluble cytosolic (S1, S2 and S3) fractions, and at lower levels in synaptosomal (LS1) and synaptic vesicle (LS2) cytosolic fractions.
4E-BP1 subcellular localization is not altered by LRRK2 deletion or G2019S LRRK2 expression compared to control mice. Endogenous and human
LRRK2 is enriched in the microsomal (P3) fraction and at lower levels in synaptosomal membrane (LP1) and soluble cytosolic (S1 and S2) fractions. The
distribution of marker proteins demonstrates the enrichment of mitochondria/heavy membranes (TIM23; P2 and LP1), synaptosomal/synaptic vesicle
membranes (synaptophysin 1; P2, P3, LP1 and LP2) and synaptosomal/synaptic vesicle cytosolic (a-synuclein; LS1 and LS2). (C) Size-exclusion
chromatography on soluble whole brain extracts from WT and LRRK2 KO mice. Sequential fractions (0.5 ml) were analyzed by Western blotting with
antibodies to total or phosphorylated (Thr37/46) 4E-BP1 and b-tubulin, whereas total homogenates were probed with antibodies to LRRK2 (c41-2/
MJFF2). The elution profile of 4E-BP1 is similar in WT and KO brains, whereas the elution profile of individual protein standards is indicated. Blots are
representative of duplicate experiments. Molecular mass markers are indicated in kilodaltons (kDa).
doi:10.1371/journal.pone.0047784.g002
Figure 3. Effect of LRRK2 on 4E-BP1 phosphorylation in mouse brain. Total 4E-BP1 immunoprecipitates or input lysates from the (A) cerebral
cortex or (B) striatum of WT and LRRK2 KO mice, or human LRRK2 (R1441C or G2019S) transgenic (TG) and non-transgenic (NTG) mice were analyzed
by Western blot analysis with antibodies to phosphorylated (Thr37/46) and total 4E-BP1, or LRRK2 (total: c41-2/MJFF2; human-selective: c81-8/MJFF4).
Densitometric analysis reveals unaltered 4E-BP1 phosphorylation by LRRK2 deletion or mutant human LRRK2 expression compared to littermate
control mice. The levels of phosphorylated 4E-BP1 were normalized to total 4E-BP1 and expressed as a percent of control mice (mean6SEM, n=3
mice/genotype). Molecular mass markers are indicated in kilodaltons (kDa).
doi:10.1371/journal.pone.0047784.g003
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study by Kumar and colleagues was unable to confirm the
phosphorylation of 4E-BP1 by LRRK2 in mammalian cells, and
further demonstrated that 4E-BP1 serves as a rather weak
substrate for LRRK2 in vitro [36]. For these reasons, we decided
to extend these prior studies to explore the contribution of LRRK2
expression and pathogenic mutations to 4E-BP1 phosphorylation
in the mammalian brain to begin to understand whether abnormal
4E-BP1 phosphorylation could contribute to LRRK2-linked PD. In
the present study, we were able to replicate previous experiments
showing that 4E-BP1 is weakly phosphorylated by LRRK2 in vitro
[25,36]. Furthermore, we could replicate recent observations from
Kumar and colleagues by similarly demonstrating unaltered 4E-
BP1 phosphorylation in HEK-293T cells transiently expressing
LRRK2 [36].
We extended these observations to mammalian brain tissue
where we could demonstrate that the deletion of LRRK2 or the
expression of human LRRK2 harboring disease-causing muta-
tions, R1441C or G2019S, failed to alter 4E-BP1 phosphorylation
at Thr37 and Thr46 in the mouse brain. Furthermore, 4E-BP1
phosphorylation at these residues was not increased in brain
extracts from idiopathic or G2019S mutant PD subjects compared
to control subjects. Further supporting the notion that 4E-BP1 is
not a physiological substrate of LRRK2 in the mammalian brain,
we could show that 4E-BP1 and LRRK2 only partially co-localize
Figure 4. Effect of LRRK2 on 4E-BP1 post-translational modification in mammalian cells and brain. (A) 2D SDS-PAGE (pH 3–10 and 8–
16% SDS-PAGE) analysis of SH-SY5Y cell extracts expressing FLAG-tagged human LRRK2 variants (WT, G2019S or D1994A). 2D blots were probed with
4E-BP1 antibody or stained with Ponceau S red to reveal equivalent protein loading. The 2D migration profile of 4E-BP1 is not altered by LRRK2
kinase-inactive (D1994A) or kinase-hyperactive (G2019S) mutations relative to WT LRRK2. 1D blots were probed with anti-FLAG antibody to reveal
equivalent human LRRK2 levels. Blots are representative of duplicate experiments. (B and C) 2D SDS-PAGE analysis of cerebral cortex and striatum
extracts derived from WT or LRRK2 KO mice with 4E-BP1 antibody or Ponceau S red as a protein loading control. The 2D profile of 4E-BP1 is not
altered by LRRK2 deletion. Blots are representative of three experiments using independent mice for each genotype. Molecular mass markers are
indicated in kilodaltons (kDa).
doi:10.1371/journal.pone.0047784.g004
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and that altering LRRK2 expression or activity does not influence
the subcellular localization of 4E-BP1 in neurons or the mouse
brain. In addition, the deletion of LRRK2 failed to alter the
formation of native 4E-BP1 protein complexes or the post-
translational modification of 4E-BP1 in the mouse brain.
Collectively, our data suggest that 4E-BP1 is not a major or
Figure 5. Phosphorylation of 4E-BP1 in brains of PD subjects. Western blot analysis of (A) frontal cortex or (B) basal ganglia soluble fractions
from human control, idiopathic PD (iPD) and G2019S LRRK2 PD subjects with antibodies to total or phosphorylated (Thr37/46) 4E-BP1, or b-actin as a
protein loading control. Molecular mass markers are indicated in kilodaltons (kDa). Densitometric analysis of 4E-BP1 phosphorylation (upper protein
band) or total 4E-BP1 levels in idiopathic or G2019S PD brains compared to control brains. The levels of phosphorylated 4E-BP1 were normalized to
total 4E-BP1, whereas total 4E-BP1 levels were normalized to b-actin levels, and expressed as a percent of control subjects (mean6SEM, n=4–5
brains/group). For basal ganglia, G2019S subject 3 was excluded from the densitometric analysis due to a lack of detectable 4E-BP1 expression.
*P,0.05 or **P,0.01 by one-way ANOVA with Newman-Keuls post-hoc analysis. ns, non-significant.
doi:10.1371/journal.pone.0047784.g005
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robust substrate of LRRK2 kinase activity in the mammalian
brain.
We speculate that important differences may exist between
mammalian and Drosophila 4E-BP1 and/or LRRK2 which may
account for the apparent phosphorylation of d4E-BP by dLRRK
in the Drosophila brain [25,35]. The nature of these potential
differences are not clear at present but could reflect alterations in
the function or subcellular localization between dLRRK and
LRRK2 and/or d4E-BP and 4E-BP1, or a combination of these
factors. For example, mammals contain two related LRRKs,
LRRK1 and LRRK2, whereas Drosophila and other invertebrates
contain a single LRRK protein indicating functional divergence in
mammals. Alternatively, it is possible that 4E-BP1 phosphoryla-
tion is stimulated by stress consistent with the phosphorylation of
4E-BP1 by the stress-activated kinase p38a [36]. In this context,
one could speculate that LRRK2-dependent 4E-BP1 phosphory-
lation may occur in aging flies due to inherent stress, as reflected
by the increased sensitivity of dLRRK transgenic flies exposed to
oxidative insult [25], whereas the LRRK2 knockout and
transgenic mice at the ages used in this study do not develop
robust brain phenotypes and might therefore be considered free of
stressful stimuli [37,38]. 4E-BP1 appears to be consistently, albeit
weakly, phosphorylated by LRRK2 in vitro yet evidence that 4E-
BP1 is a robust substrate of LRRK2 in vivo is lacking [25,36].
These observations highlight the importance of verifying LRRK2
substrate phosphorylation in mammalian cells or tissues to confirm
or clarify the physiological relevance of putative LRRK2
substrates. In future, we hope to apply similar analyses to other
putative or novel LRRK2 substrates pending the availability of
suitable phosphorylation-specific substrate antibodies. Taken
together, our data allow us to conclude that 4E-BP1 is not a
major or robust physiological substrate of LRRK2 kinase activity
in vivo in the mammalian brain. We suggest that attention should
now focus on other putative LRRK2 substrates to confirm or




For use of human brain tissue in this study, patients provided
written informed consent and approval for the consent procedure
and experiments were obtained from the NHS National Research
Ethics Committee of the UK (Approval No. 02/N093). All animal
experiments were approved by the SCAV (Service de la
consummation et des affaires veterinaries) in the Canton de Vaud,
Switzerland (Animal authorization No. 2293), and conducted in
strict accordance with the European Union directive (2010/63/
EU) for the care and use of laboratory animals.
Animals
Mice and rats were maintained in a pathogen-free barrier
facility and exposed to a 12 h light/dark cycle with food and water
provided ad libitum. Pregnant female Sprague-Dawley rats were
obtained from Charles River Laboratories (L’Arbresle Cedex,
France) and resulting P1 rats were used for preparation of primary
cortical neuronal cultures. LRRK2 knockout mice with a deletion
of exon 41 were kindly provided by Drs. Giorgio Rovelli and
Derya Shimshek (Novartis Pharma AG, Basel, Switzerland) [37].
Transgenic mice expressing full-length human LRRK2 (R1441C
or G2019S) from a CMV-enhanced human PDGFb promoter
were described previously [38].
Expression plasmids, antibodies and proteins
Mammalian expression plasmids containing FLAG-tagged full-
length human WT and G2019S LRRK2 were kindly provided by
Dr. Christopher Ross (Johns Hopkins University, Baltimore, USA)
[20]. A D1994A mutation was introduced into FLAG-tagged WT
LRRK2 by PCR-mediated site-directed mutagenesis using the
QuickChange II XL kit (Agilent Technologies, La Jolla, CA, USA)
and verified by DNA sequencing. Myc-tagged full-length human
LRRK2 (WT, G2019S and D1994A) plasmids were kindly
provided by Dr. Ted M. Dawson (Johns Hopkins University,
Baltimore, USA) [17]. The following antibodies were employed:
mouse monoclonal anti-FLAG (M2), anti-FLAG (M2)-peroxidase
and anti-b-tubulin (clone TUB 2.1), and rabbit polyclonal anti-b-
actin (Sigma-Aldrich, Buchs, Switzerland); rabbit monoclonal anti-
LRRK2 (clones MJFF2/c41-2 and MJFF4/c81-8; Epitomics Inc.,
Burlingame, CA, USA); rabbit monoclonal anti-4E-BP1 (clone
53H11), anti-phospho-4E-BP1 (Thr37/46; clone 236B4) and anti-
phospho-4E-BP1 (Ser65; clone 174A9) (Cell Signaling Technolo-
gy, Danvers, MA); mouse monoclonal anti-c-myc-peroxidase
(clone 9E10; Roche Applied Science, Switzerland); mouse
monoclonal anti-TIM23 (clone 32) and a-synuclein (Syn1, clone
42) (BD Biosciences, Allschwil, Switzerland); mouse monoclonal
anti-synaptophysin 1 (Synaptic Systems, Go¨ttingen, Germany);
peroxidase-conjugated anti-mouse and anti-rabbit IgG, light
chain-specific secondary antibodies (Jackson ImmunoResearch,
Inc., West Grove, PA, USA); anti-rabbit IgG-AlexaFluor-488 and
anti-mouse IgG-AlexaFluor-633 (Invitrogen, Carlsbad, CA, USA).
Recombinant GST-tagged human LRRK2 proteins (DN, residues
970-2527) were obtained from Invitrogen. GST-tagged full-length
human 4E-BP1 was obtained from Sigma-Aldrich.
Cell culture and transient transfection
Human SH-SY5Y neuroblastoma cells (CRL-2266; ATCC,
Manassas, VA, USA [39]) and HEK-293T cells (Invitrogen) were
maintained in Dulbecco’s modified Eagle’s media supplemented
with 10% fetal bovine serum and 1x penicillin/streptomycin at
37uC in a 5% CO2 humidified atmosphere. For transient
transfection, cells were transfected with plasmid DNAs using
FuGENE HD reagent (Roche Applied Science) according to
manufacturer’s recommendations. Cells were routinely harvested
at 48 h post-transfection for Western blot analysis.
Primary neuronal cultures
Sprague-Dawley P1 rats were sacrificed by decapitation, whole
brains were dissected, and the cerebral cortices were stereoscop-
ically isolated and dissociated in media containing papain (20 U/
ml; Sigma). Cells were grown in 35 mm dishes on glass coverslips
pre-coated with mouse laminin (33 mg/ml; Invitrogen) and poly-
D-lysine (20 ng/ml; BD Biosciences, Allschwil, Switzerland) in
media consisting of Neurobasal (Invitrogen), B27 supplement (2%
w/v), L-glutamine (500 mM) and penicillin/streptomycin (100 U/
ml). At days-in-vitro (DIV) 3, cortical cultures were treated with
cytosine b-D-arabinofuranoside (AraC, 10 mM) to inhibit glial cell
division. For infection with adenoviral vectors, we used 36108
infectious units on dishes containing 36105 cells to give a MOI of
1000.
Adenovirus production
Second generation E1, E3, E2a-deleted recombinant human
serotype 5 adenoviruses (rAd) were generated as previously
described [40,41]. A modified version of the pDC511 shuttle
plasmid (Microbix Biosystems Inc., Ontario, Canada) was
generated containing an expression cassette consisting of a human
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synapsin-1 promoter, a synthetic intron, codon-optimized
3xFLAG-tagged human LRRK2 cDNA (WT, G2019S or
R1441C) and a SV40 polyadenylation signal, as previously
described [41,42]. Each pDC511-LRRK2 shuttle plasmid was
co-transfected with a modified FLP, frt human Ad5 genomic
plasmid (pBHGfrtDE1,3FLP; Microbix) into E2a-complementing
cells (E2T) [40], and rAd production was performed according to
a standard protocol [43]. Final vector stocks were purified and
concentrated using the Vivapure AdenoPACK 100RT kit
(Sartorius). Viral titers of purified vector stocks were determined
by OD260 measurements and expressed as viral particles. To
determine MOI units, we estimated that 1 MOI is equivalent to 40
viral particles (assuming that on average 1 out of 40 viral particles
are infectious). Adenovirus stocks were stored at -80uC until
further use.
Cell fractionation and Western blotting
Transiently transfected HEK-293T or SH-SY5Y were harvest-
ed at 48 h post-transfection in 1 ml of lysis buffer (1X phosphate-
buffered saline [PBS] pH 7.4, 1% Triton X-100, 1X phosphatase
inhibitor cocktail 1 and 2 [Sigma-Aldrich], 1X Complete protease
inhibitor cocktail [Roche Applied Sciences]). Cell lysates were
rotated at 4uC for 1 h and soluble fractions were obtained by
centrifugation at 17,500 g for 15 min at 4uC. Protein concentra-
tion of detergent-soluble fractions was determined by BCA assay
(Pierce Biotechnology, Rockford, IL, USA). For western blot
analysis, 50 mg of protein was resolved by SDS-PAGE, transferred
to Protran nitrocellulose membrane (0.2 mm; Perkin Elmer,
Schwerzenbach, Switzerland) and incubated with primary and
secondary antibodies. Proteins were visualized by enhanced
chemiluminescence (ECL; GE Healthcare, Glattbrugg, Switzer-
land) on a FujiFilm LAS-4000 Luminescent Image Analysis
system. Quantitation of protein levels by densitometry was
conducted on acquired images using LabImage 1D software
(Kapelan Bio-Imaging Solutions, Leipzig, Germany).
Brain fractionation and immunoprecipitation
Mice were sacrificed by cervical dislocation and decapitation
and whole brains were rapidly removed and dissected and frozen
on dry ice. For immunoprecipitation (IP) assays, the cerebral
cortex and striatum from adult wild-type and LRRK2 KO mice
(with targeted deletion of exon 41) or human R1441C or G2019S
LRRK2 transgenic and non-transgenic mice was employed. Brain
extracts were prepared by homogenization in TEN buffer
(100 mM Tris-HCl pH 7.5; 100 mM NaCl; 10 mM EDTA;
0.5% NP-40) supplemented with 1X phosphatase inhibitor
cocktail 1 and 2 (Sigma-Aldrich) and 1X Complete protease
inhibitor cocktail (Roche Applied Sciences), and clarified by
centrifugation at 100,000 g for 20 min at 4uC. The detergent-
soluble supernatant fraction was quantified by BCA assay (Pierce
Biotechnology). Detergent-soluble fractions (5–10 mg of protein)
were incubated with 50 ml Protein G-Dynabeads (Invitrogen) pre-
incubated with 5 mg of rabbit monoclonal anti-4E-BP1 antibody
(clone 53H11; Cell Signaling Technology) followed by overnight
rotation at 4uC. Dynabead complexes were sequentially washed
twice with TEN buffer supplemented with 500 mM NaCl and
twice with TEN buffer alone. Immunoprecipitates were eluted by
heating at 70uC for 10 min in 2X Laemmli sample buffer (Bio-
Rad AG, Reinach, Switzerland) containing 5% 2-mercaptoetha-
nol. IP and input lysates (50 mg of protein) were resolved by SDS-
PAGE, transferred to Protran nitrocellulose (0.2 mm; Perkin
Elmer, Schwerzenbach, Switzerland), and subjected to Western
blot analysis with anti-4E-BP1 (clone 53H11; Cell Signaling
Technology), anti-phospho-4E-BP1(Thr37/46) (clone 236B4; Cell
Signaling 53H11), or anti-LRRK2 antibodies (clones c41-2/
MJFF2 or c81-8/MJFF4; Epitomics, Inc.) and appropriate
secondary antibodies. Proteins were visualized by enhanced
chemiluminescence (ECL; GE Healthcare, Glattbrugg, Switzer-
land) on a FujiFilm LAS-4000 Luminescent Image Analysis
system. Quantitation of protein levels by densitometry was
conducted on acquired images using LabImage 1D software
(Kapelan Bio-Imaging Solutions, Leipzig, Germany).
Two-dimensional SDS-PAGE
Mice were sacrificed by cervical dislocation and decapitation
and whole brains were rapidly removed and dissected and frozen
on dry ice. Brain extracts were resolved by 2D SDS-PAGE (1st
dimension: pH 3–10, non-linear gradient IEF strips; 2nd dimen-
sion: 8-16% gradient SDS-PAGE) using the ZOOM IPGRunner
system (Invitrogen) according to manufacturer’s instructions.
Briefly, brain proteins (150 mg) were rehydrated in 160 ml of
rehydration buffer (8 M Urea, 2% CHAPS, 0.5% Carrier
Ampholytes (Invitrogen), 0.002% Bromphenol Blue) and loaded
on ZOOM IPG Strips (pH 3–10, non-linear gradient) in the
ZOOM IPGRunner system for 1 h at room temperature. Proteins
were first separated using isoelectric focusing (step 1: 200 V/
70 Vh; step 2: 430 V/120 Vh; step 3: 750 V/200 Vh; step 4:
200 V/1650 Vh), re-equilibrated with DTT-equilibration buffer
(75 mM Tri-HCl pH 8.8, 6 M Urea, 30% glycerol, 2% SDS,
0.002% Bromphenol Blue and 125 mM DTT) for 10 min at room
temperature and then with alkylating solution (75 mM Tri-HCl
pH 8.8, 6 M Urea, 30% glycerol, 2% SDS, 0.002% Bromphenol
Blue and 125 mM iodoacetamide) for 10 min at room tempera-
ture. Proteins were resolved in the second dimension by SDS-
PAGE using 8-16% gradient gels (Invitrogen). Following 2D SDS-
PAGE, proteins were either transferred to nitrocellulose for
Western blot analysis with anti-4E-BP1 antibody or gels were
sequentially stained with ProQ Diamond fluorescent stain (532/
560 nm ex/em; Invitrogen) and Coomassie colloidal blue (G250;
Bio-rad) and images were captured on a GE Typhoon 9400
Imager. For 2D SDS-PAGE analysis of SH-SY5SY cells, cells
transiently transfected with FLAG-tagged human LRRK2 (WT,
G2019S or D1994A) plasmids were harvested at 48 h post-
transfection, lysed and cell extracts (200 mg protein) were subjected
to 2D SDS-PAGE as described above.
Subcellular fractionation of mouse brain
Mice were sacrificed by cervical dislocation and decapitation
and whole brains were rapidly removed and dissected and frozen
on dry ice. Subcellular fractionation was conducted as described
previously [44,45,46] using cerebral cortex tissue from adult wild-
type and LRRK2 KO mice or human R1441C or G2019S
LRRK2 transgenic and non-transgenic mice. Briefly, mouse brain
homogenates were subjected to centrifugation at 800 g for 10 min
at 4uC to obtain pellet nuclear/whole cell (P1) and soluble
cytosolic (S1) fractions. S1 fractions were centrifuged at 9,200 g for
15 min at 4uC to obtain heavy membrane (P2) and soluble
cytosolic (S2) fractions. The P2 fraction was further solublized and
centrifuged at 25,000 g for 20 min at 4uC to enrich synaptosomal
membranes (LP1) and synaptosomal cytosolic (LS1) fractions. The
LS1 fraction was further fractionated by ultracentrifugation at
165,000 g for 2 h at 4uC to produce synaptic vesicle-enriched
(LP2) and cytosolic (LS2) fractions. To enrich light membranes/
microsomes (P3), the S2 fraction was subjected to ultracentrifu-
gation at 165,000 g for 2 h at 4uC. Protein concentrations were
determined by BCA assay (Pierce Biotechnology) and equal
quantities of each fraction were assessed by Western blotting with
specific antibodies labeling mitochondria (TIM23; P2 and LP1),
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synaptosomes/synaptic vesicles (synaptophysin 1; P2, P3, LP1 and
LP2), and synaptosomal/synaptic vesicle cytosolic (a-synuclein;
LS1 and LS2) subcellular compartments.
Size-exclusion chromatography of mouse brain
Size-exclusion chromatography was performed at 4uC using an
Akta-FPLC system (Amersham Biosciences). Mice were sacrificed
by cervical dislocation and decapitation and whole brains were
rapidly removed. Whole brains from adult wild-type or LRRK2
KO mice were homogenized on ice for 30 min in lysis buffer
(0.1% Triton X-100 in 1X PBS containing 1X Complete protease
inhibitor cocktail [Roche Applied Sciences]), briefly centrifuged,
and cleared lysates were injected for FPLC. Gel filtration was
conducted using a Superdex 200 10/300 GL column (Amersham
Biosciences) equilibrated with lysis buffer at 0.4 ml/min. Column
void volume was 8 ml, and elution volumes of standards were 9 ml
for thyroglobulin (669 kDa), 10.5 ml for ferritin (440 kDa),
12.5 ml for aldolase (158 kDa), 15.5 ml for conalbumin
(75 kDa), and 16.5 ml for ovalbumin (43 kDa). Fractions
(0.5 ml) were analyzed by SDS-PAGE and Western blotting with
anti-4E-BP1, anti-phospho-4E-BP1 (Thr37/46) and b-tubulin
antibodies.
Human brain tissue
Human tissue for these studies was obtained from the archive at
Queen Square Brain Bank (QSBB). These include 4 G2019S
subjects, 5 idiopathic PD and 5 control brain subjects. Frontal
cortex tissue was obtained for a fifth G2019S subject from Sun
Health Research Institute, USA. The details of these human
subjects are listed in Table 1. Written informed consent was
obtained from all patients and approval for this study was obtained
from the NHS National Research Ethics Committee of the UK.
The 4 G2019S PD subjects from the QSBB brain bank were
classified neuropathologically as the limbic subtype for Lewy body
pathology according to McKeith consensus criteria for the
classification of DLBs [47]. In this limbic subtype, Lewy bodies
are present in brainstem and substantia nigra, and are also
prominently present in the limbic regions of the cortex i.e.
amygdala, transentorhinal and cingulate regions, but very few
Lewy bodies are detected in the frontal, temporal and parietal
cortices. The fifth G2019S subject, from Sun Health, also harbored
limbic subtype Lewy body pathology. The iPD subjects chosen
were matched for pathology with the G2019S subjects, while the
controls had no signs of any significant neuropathology and did
not suffer from any neurological disease. Flash-frozen tissue was
obtained from the basal ganglia and frontal cortex of these
subjects.
Fractionation of human brain tissue
10% (w/v) homogenates were prepared from 1 g tissue from
basal ganglia and frontal cortex regions in homogenization buffer
(20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1X Complete protease
inhibitor cocktail [Roche Applied Sciences] and 1X phosphatase
inhibitor cocktail [Roche Applied Sciences]) with the aid of a
mechanical homogenizer, and cleared by centrifugation at 1,000 g
for 5 min at 4uC. Protein concentrations of cleared homogenates
were calculated by BCA assay (Pierce Biotechnology). Thirty mg of
protein were resolved on 18% Bis-Tris gels (Invitrogen) using
MOPS buffer and transferred onto PVDF membranes. Blots were
probed with anti-4E-BP1 and anti-phospho-4E-BP1 (Thr37/46)
(Cell Signaling Technology), or b-actin (Sigma-Aldrich) antibod-
ies, and appropriate peroxidase-conjugated secondary antibodies.
Enhanced chemiluminescence (Pierce) images were captured onto
X-Omat films (Kodak). Quantitation of protein levels by
densitometry was conducted on scanned images using LabImage
1D software (Kapelan Bio-Imaging Solutions). For quantitation of
phospho-4E-BP1 levels, the upper protein band corresponding to
4E-BP1 was used for densitometry.
Immunocytochemistry and confocal microscopy
For co-localization of LRRK2 and 4E-BP1, rat primary cortical
cultures were infected with adenoviral vectors expressing FLAG-
tagged human LRRK2 variants (WT, R1441C or G2019S) at
DIV 6, fixed at DIV 16 with 4% paraformaldehyde (PFA), and
subjected to immunocytochemistry with mouse anti-FLAG-(M2)
antibody and rabbit anti-4E-BP1 antibody followed by anti-mouse
IgG-AlexaFluor-633 and anti-rabbit IgG-AlexaFluor-488 antibod-
ies (Invitrogen). Fluorescent images were acquired using a Zeiss
LSM 700 inverted confocal microscope (Carl Zeiss AG, Feldbach,
Switzerland) with a Plan-Apochromat 63x/1.40 oil objective in x,
y and z planes and analyzed using NIH Image J software. Images
were subjected to deconvolution using HuygensPro software
(Scientific Volume Imaging, Hilversum, Netherlands). Represen-
tative images are taken from a single z-plane at a thickness of
0.1 mm.
In vitro radioactive kinase assays
Recombinant GST-tagged human LRRK2 protein (D970-
2527; WT or D1994A, Invitrogen) was incubated with recombi-
nant GST-tagged human 4E-BP1 (Sigma-Aldrich) in kinase assay
buffer (20 mM Tris pH 7.4, 5 mM EGTA and 20 mM b-glycerol
phosphate in 1X PBS). Reactions were initiated by addition of
activation buffer to final concentrations that includes 0.1 mM
[32P]-c-ATP (0.2 mCi/reaction) and 20 mM MgCl2 and incuba-
tion at 30uC with shaking for 30 min. Reactions were terminated
by placing the tubes on ice and proteins were resolved on SDS-
PAGE gels and exposed to phospho-imager screens to detect 32P
incorporation followed by staining with Coomassie colloidal blue.
Table 1. Clinical details of human brain tissue.
Subject Gender Age (yrs) PMD (h) Pathology
G2019S 1 F 80 44.4 Limbic
G2019S 2 F 81 15 Limbic
G2019S 3 F 84 32.2 Limbic
G2019S 4 F 72 24.55 Limbic
G2019S 5 M 85 1.66 Limbic
iPD 1 F 69 52.5 Limbic
iPD 2 M 70 61.2 Limbic
iPD 3 F 87 47.45 Limbic
iPD 4 M 75 48 Limbic
iPD 5 F 88 11.3 Limbic
Control 1 F 85 37 N/A
Control 2 M 93 112 N/A
Control 3 F 91 98.5 N/A
Control 4 M 87 36 N/A
Control 5 F 68 41.5 N/A
Abbreviations: iPD, idiopathic Parkinson’s disease; Limbic, limbic
subtype of Lewy body pathology according to McKeith consensus
criteria for the classification of DLB; N/A, non-applicable; PMD,
post mortem delay; yrs, years.
doi:10.1371/journal.pone.0047784.t001
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Statistical analysis
Data were analyzed by two-tailed, unpaired Student’s t-test for
pair-wise comparisons, or by one-way ANOVA with Newman-
Keuls post-hoc analysis for comparison of multiple data groups, as
indicated. P,0.05 was considered significant.
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